Why do cgrp cause constipation

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: CGRP (calcitonin gene-related peptide) causes constipation primarily by inhibiting gastrointestinal motility through its action on smooth muscle and enteric neurons. Specifically, CGRP binds to receptors in the gut, reducing acetylcholine release and slowing peristalsis, with studies showing constipation in 3-5% of patients on CGRP monoclonal antibodies. This side effect was noted in clinical trials for migraine prevention drugs like erenumab (approved by the FDA in 2018) and fremanezumab.

Key Facts

CGRP monoclonal antibodies cause constipation in 3-5% of patients according to clinical trial data
Erenumab (Aimovig) was the first FDA-approved CGRP monoclonal antibody in May 2018
CGRP inhibits acetylcholine release in enteric neurons by 30-50% in animal studies
Constipation from CGRP drugs typically develops within weeks of starting treatment
CGRP receptors are found throughout the gastrointestinal tract, particularly in the colon

Overview

CGRP (calcitonin gene-related peptide) is a neuropeptide discovered in 1982 that plays multiple roles in pain transmission, vasodilation, and gastrointestinal function. In migraine pathophysiology, CGRP levels increase during attacks, making it a target for preventive treatments. The development of CGRP-targeted therapies began in the early 2000s, leading to FDA approval of the first CGRP monoclonal antibody, erenumab (Aimovig), in May 2018. These drugs work by blocking CGRP or its receptors to prevent migraines, but their systemic effects extend beyond the nervous system. Constipation emerged as a notable side effect during clinical trials, affecting thousands of patients worldwide. As of 2023, over 2 million patients have been treated with CGRP-targeted therapies globally, with gastrointestinal issues being one of the most common adverse effects reported to regulatory agencies.

How It Works

CGRP causes constipation through multiple mechanisms in the gastrointestinal tract. First, CGRP binds to CGRP receptors (primarily CLR/RAMP1 complexes) on enteric neurons, inhibiting acetylcholine release by 30-50% in animal models. Acetylcholine is crucial for stimulating smooth muscle contractions that propel food through the digestive system. Second, CGRP directly relaxes gastrointestinal smooth muscle by increasing cyclic AMP levels, slowing peristalsis. Third, CGRP affects interstitial cells of Cajal, which coordinate gut motility rhythms. In the colon specifically, CGRP reduces propulsive contractions and increases segmentation, leading to prolonged transit times. This is why constipation from CGRP drugs typically develops within 2-4 weeks of starting treatment and can persist as long as the medication is continued.

Why It Matters

Understanding CGRP-induced constipation is clinically important because CGRP-targeted therapies are now first-line preventive treatments for millions of migraine patients worldwide. Constipation affects 3-5% of patients on these drugs, potentially leading to treatment discontinuation in severe cases. This side effect has practical implications for patient management, requiring monitoring and sometimes prophylactic measures like increased fiber intake or stool softeners. Research into CGRP's gastrointestinal effects also contributes to broader understanding of neuro-gut interactions, with potential applications in irritable bowel syndrome and other motility disorders. The FDA continues to monitor post-marketing reports of gastrointestinal adverse events from CGRP drugs, making this an ongoing area of pharmacovigilance concern.